These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26341633)

  • 1. Pattern and predictors of immunologic recovery in HIV infected patients.
    Kwofie TB; Owusu M; Mutocheluh M; Nguah SB; Obeng-Baah J; Hanson C; Dompreh A
    BMC Res Notes; 2015 Sep; 8():413. PubMed ID: 26341633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
    Gezie LD
    BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunological response of HIV-positive patients initiating HAART at the Komfo Anokye Teaching Hospital, Kumasi, Ghana.
    Annison L; Dompreh A; Adu-Sarkodie Y
    Ghana Med J; 2013 Dec; 47(4):164-70. PubMed ID: 24669021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
    Lawn SD; Myer L; Bekker LG; Wood R
    BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study.
    Gunda DW; Kilonzo SB; Kamugisha E; Rauya EZ; Mpondo BC
    BMC Res Notes; 2017 Jun; 10(1):197. PubMed ID: 28595630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India.
    Rajasekaran S; Jeyaseelan L; Raja K; Vijila S; Krithigaipriya KA; Kuralmozhi R
    J Postgrad Med; 2009; 55(4):261-6. PubMed ID: 20083872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial.
    Soria A; Trabattoni D; Squillace N; Rainone V; Gnudi F; Clerici M; Gori A; Bandera A
    PLoS One; 2015; 10(2):e0117118. PubMed ID: 25671649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
    Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
    Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients.
    Chow WZ; Lim SH; Ong LY; Yong YK; Takebe Y; Kamarulzaman A; Tee KK
    PLoS One; 2015; 10(9):e0137281. PubMed ID: 26335136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
    Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.